Hypomyelinating leukodystrophies: Translational research progress and prospects

Annals of Neurology

Volumn 76, Issue 1, 2014, Pages 5-19

  Pouwels, Petra J W ^a   Vanderver, Adeline ^b   Bernard, Genevieve ^c   Wolf, Nicole I ^a   Dreha Kulczewksi, Steffi F ^d   Deoni, Sean C L ^e   Bertini, Enrico ^f   Kohlschütter, Alfried ^g   Richardson, William ^h   Ffrench Constant, Charles ^h   Köhler, Wolfgang ⁱ   Rowitch, David ^j   Barkovich, A James ^k  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c MONTREAL CHILDREN S HOSPITAL   (Canada)

^d UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^e Brown University   (United States)

^f BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ UNIVERSITY OF EDINBURGH   (United Kingdom)

^j Hospital Hubertusburg   (Germany)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MYELIN;

BLOOD BRAIN BARRIER; DISEASE CLASSIFICATION; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HYPOMYELINATING LEUKODYSTROPHY; LEUKODYSTROPHY; MYELINATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; TRANSLATIONAL RESEARCH;

HEREDITARY CENTRAL NERVOUS SYSTEM DEMYELINATING DISEASES; HUMANS; MAGNETIC RESONANCE IMAGING; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84904750732     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24194     Document Type: Review

References (114)

1. Schiffmann R, Moller JR, Trapp BD, et al. Childhood ataxia with diffuse central nervous system hypomyelination. Ann Neurol 1994; 35: 331-340.
2. Schiffmann R, van der Knaap MS,. Invited article: An MRI-based approach to the diagnosis of white matter disorders. Neurology 2009; 72: 750-759.
3. Steenweg ME, Vanderver A, Blaser S, et al. Magnetic resonance imaging pattern recognition in hypomyelinating disorders. Brain 2010; 133: 2971-2982.
4. Baumann N, Pham-Dinh D,. Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol Rev 2001; 81: 871-927.
5. Bradl M, Lassmann H,. Oligodendrocytes: biology and pathology. Acta Neuropathol 2010; 119: 37-53.
6. Funfschilling U, Supplie LM, Mahad D, et al. Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature 2012; 485: 517-521.
7. Morrison BM, Lee Y, Rothstein JD,. Oligodendroglia: metabolic supporters of axons. Trends Cell Biol 2013; 23: 644-651.
8. Paz Soldán MM, Pirko I,. Biogenesis and significance of central nervous system myelin. Semin Neurol 2012; 32: 9-14.
9. Freeman MR, Rowitch DH,. Evolving concepts of gliogenesis: a look way back and ahead to the next 25 years. Neuron 2013; 80: 613-623.
10. Baron W, Hoekstra D,. On the biogenesis of myelin membranes: sorting, trafficking and cell polarity. FEBS Lett 2010; 584: 1760-1770.
11. Webster H,. The geometry of peripheral myelin sheaths during their formation and growth in rat sciatic nerves. J Cell Biol 1971; 48: 348-367.
12. Harris JJ, Attwell D,. The energetics of CNS white matter. J Neurosci 2012; 32: 356-371.
13. Lee Y, Morrison BM, Li Y, et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature 2012; 487: 443-448.
14. Rinholm JE, Hamilton NB, Kessaris N, et al. Regulation of oligodendrocyte development and myelination by glucose and lactate. J Neurosci 2011; 31: 538-548.
15. Franklin RJM, ffrench-Constant C,. Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci 2008; 9: 839-855.
16. Young KM, Psachoulia K, Tripathi RB, et al. Oligodendrocyte dynamics in the healthy adult CNS: evidence for myelin remodeling. Neuron 2013; 77: 873-885.
17. Fancy SPJ, Chan JR, Baranzini SE, et al. Myelin regeneration: a recapitulation of development? Annu Rev Neurosci 2011; 34: 21-43.
18. Snaidero N, Möbius W, Czopka T, et al. Myelin membrane wrapping of CNS axons by PI(3,4,5)P3-dependent polarized growth at the inner tongue. Cell 2014; 156: 277-290.
19. Dhaunchak AS, Colman DR, Nave K-A,. Misalignment of PLP/DM20 transmembrane domains determines protein misfolding in Pelizaeus-Merzbacher disease. J Neurosci 2011; 31: 14961-14971.
20. Wolf NI, van der Knaap MS,. AGC1 deficiency and cerebral hypomyelination. N Engl J Med 2009; 361: 1997-1998; author reply 1998.
21. Wibom R, Lasorsa FM, Tohonen V, et al. AGC1 deficiency associated with global cerebral hypomyelination. N Engl J Med 2009; 361: 489-495.
22. Magen D, Georgopoulos C, Bross P, et al. Mitochondrial hsp60 chaperonopathy causes an autosomal-recessive neurodegenerative disorder linked to brain hypomyelination and leukodystrophy. Am J Hum Genet 2008; 83: 30-42.
23. Boespflug-Tanguy O, Aubourg P, Dorboz I, et al. Neurodegenerative disorder related to AIMP1/p43 mutation is not a PMLD. Am J Hum Genet 2011; 88: 392-393; author reply 393-395.
24. Feinstein M, Markus B, Noyman I, et al. Pelizaeus-Merzbacher-like disease caused by AIMP1/p43 homozygous mutation. Am J Hum Genet 2010; 87: 820-828.
25. Orthmann-Murphy JL, Enriquez AD, Abrams CK, Scherer SS,. Loss-of-function GJA12/connexin47 mutations cause Pelizaeus-Merzbacher-like disease. Mol Cell Neurosci 2007; 34: 629-641.
26. Pingault V, Guiochon-Mantel A, Bondurand N, et al. Peripheral neuropathy with hypomyelination, chronic intestinal pseudo-obstruction and deafness: a developmental "neural crest syndrome" related to a SOX10 mutation. Ann Neurol 2000; 48: 671-676.
27. Tetreault M, Choquet K, Orcesi S, et al. Recessive mutations in POLR3B, encoding the second largest subunit of Pol III, cause a rare hypomyelinating leukodystrophy. Am J Hum Genet 2011; 89: 652-655.
28. Bernard G, Chouery E, Putorti ML, et al. Mutations of POLR3A encoding a catalytic subunit of RNA polymerase Pol III cause a recessive hypomyelinating leukodystrophy. Am J Hum Genet 2011; 89: 415-423.
29. Vanderver A, Tonduti D, Schiffmann R, Schmidt J, Van der Knaap MS,. Leukodystrophy overview. 2014. Available at: http://www.ncbi.nlm.nih.gov/books/ NBK184570/.
30. Takanashi J, Inoue K, Tomita M, et al. Brain N-acetylaspartate is elevated in Pelizaeus-Merzbacher disease with PLP1 duplication. Neurology 2002; 58: 237-241.
31. Takanashi J, Saito S, Aoki I, et al. Increased N-acetylaspartate in mouse model of Pelizaeus-Merzbacher disease. J Magn Reson Imaging 2012; 35: 418-425.
32. Hanefeld FA, Brockmann K, Pouwels PJW, et al. Quantitative proton MRS of Pelizaeus-Merzbacher disease. Evidence of dys- and hypomyelination. Neurology 2005; 65: 701-706.
33. Wilhelm MJ, Ong HH, Wehrli SL, et al. Direct magnetic resonance detection of myelin and prospects for quantitative imaging of myelin density. Proc Natl Acad Sci U S A 2012; 109: 9605-9610.
34. Kreis R, Ernst T, Ross BD,. Absolute quantitation of water and metabolites in the human brain. II. Metabolite concentrations. J Magn Reson 1993; 102: 9-15.
35. Barkovich AJ, Kjos BO, Jackson DE Jr, Norman D,. Normal maturation of the neonatal and infant brain: MR imaging at 1.5 T. Radiology 1988; 166: 173-180.
36. Kreis R, Ernst T, Ross BD,. Development of the human brain: in vivo quantification of metabolite and water content with proton magnetic resonance spectroscopy. Magn Reson Med 1993; 30: 424-437.
37. Kreis R, Hofmann L, Kuhlmann B, et al. Brain metabolite composition during early human brain development as measured by quantitative in vivo 1H magnetic resonance spectroscopy. Magn Reson Med 2002; 48: 949-958.
38. van der Voorn JP, Pouwels PJW, Hart AAM, et al. Childhood white matter disorders: quantitative MR imaging and spectroscopy. Radiology 2006; 241: 510-517.
39. Takanashi J, Nitta N, Iwasaki N, et al. Neurochemistry in shiverer mouse depicted on MR spectroscopy. J Magn Reson Imaging 2014; 39: 1550-1557.
40. Moffett JR, Ross B, Arun P, et al. N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol 2007; 81: 89-131.
41. Gow A, Southwood CM, Lazzarini RA,. Disrupted proteolipid protein trafficking results in oligodendrocyte apoptosis in an animal model of Pelizaeus-Merzbacher disease. J Cell Biol 1998; 140: 925-934.
42. Jansen JFA, Shamblott MJ, van Zijl PCM, et al. Stem cell profiling by nuclear magnetic resonance spectroscopy. Magn Reson Med 2006; 56: 666-670.
43. Bloembergen N, Purcell EM, Pound RV,. Relaxation effects in nuclear magnetic resonance absorption. Phys Rev 1948; 73: 679-715.
44. Paus T, Collins DL, Evans AC, et al. Maturation of white matter in the human brain: a review of magnetic resonance studies. Brain Res Bull 2001; 54: 255-266.
45. Laule C, Vavasour IM, Leung E, et al. Pathological basis of diffusely abnormal white matter: insights from magnetic resonance imaging and histology. Mult Scler 2011; 17: 144-150.
46. Gelman N, Ewing JR, Gorell JM, et al. Interregional variation of longitudinal relaxation rates in human brain at 3.0T: relation to estimated iron and water contents. Magn Reson Med 2001; 45: 71-79.
47. Hoque R, Ledbetter C, Gonzalez-Toledo E, et al. The role of quantitative neuroimaging indices in the differentiation of ischemia from demyelination: an analytical study with case presentation. In:, Alireza M, ed. International review of neurobiology. Waltham, MA: Academic Press, 2007: 491-519.
48. Menon RS, Rusinko MS, Allen PS,. Multiexponential proton relaxation in model cellular systems. Magn Reson Med 1991; 20: 196-213.
49. Mackay A, Whittall K, Adler J, et al. In vivo visualization of myelin water in brain by magnetic resonance. Magn Reson Med 1994; 31: 673-677.
50. Kroeker RM, Henkelman RM,. Analysis of biological NMR relaxation data with continuous distributions of relaxation times. J Magn Reson 1986; 69: 218-235.
51. Whittall KP, MacKay AL, Graeb DA, et al. In vivo measurement of T2 distributions and water contents in normal human brain. Magn Reson Med 1997; 40: 34-43.
52. MacKay A, Laule C, Vavasour I, et al. Insights into brain microstructure from the T2 distribution. Magn Reson Imaging 2006; 24: 515-525.
53. Webb S, Munro CA, Midha R, Stanisz GJ,. Is multicomponent T2 a good measure of myelin content in peripheral nerve? Magn Reson Med 2003; 49: 638-645.
54. Laule C, Leung E, Li DK, et al. Myelin water imaging in multiple sclerosis: quantitative correlations with histopathology. Mult Scler 2006; 12: 747-753.
55. Laule C, Vavasour IM, Moore GRW, et al. Water content and myelin water fraction in multiple sclerosis. J Neurol 2004; 251: 284-293.
56. Gareau PJ, Rutt BK, Karlik SJ, Mitchell JR,. Magnetization transfer and multicomponent T2 relaxation measurements with histopathologic correlation in an experimental model of MS. J Magn Reson Imaging 2000; 11: 586-595.
57. Labadie C, Lee J-H, Rooney WD, et al. Myelin water mapping by spatially regularized longitudinal relaxographic imaging at high magnetic fields. Magn Reson Med 2014; 71: 375-387.
58. Vavasour IM, Laule C, Li DKB, et al. Is the magnetization transfer ratio a marker for myelin in multiple sclerosis? J Magn Reson Imaging 2011; 33: 710-718.
59. Mädler B, Drabycz SA, Kolind SH, et al. Is diffusion anisotropy an accurate monitor of myelination? Correlation of multicomponent T2 relaxation and diffusion tensor anisotropy in human brain. Magn Reson Imaging 2008; 26: 874-888.
60. Oh J, Han ET, Pelletier D, Nelson SJ,. Measurement of in vivo multi-component T2 relaxation times for brain tissue using multi-slice T2 prep at 1.5 and 3 T. Magn Reson Imaging 2006; 24: 33-43.
61. Prasloski T, Rauscher A, MacKay AL, et al. Rapid whole cerebrum myelin water imaging using a 3D GRASE sequence. Neuroimage 2012; 63: 533-539.
62. Deoni SCL, Rutt BK, Arun T, et al. Gleaning multicomponent T1 and T2 information from steady-state imaging data. Magn Reson Med 2008; 60: 1372-1387.
63. Lankford CL, Does MD,. On the inherent precision of mcDESPOT. Magn Reson Med 2013; 69: 127-136.
64. Deoni SC, Dean DC III, O'Muircheartaigh J,. Investigating white matter development in infancy and early childhood using myelin water faction and relaxation time mapping. Neuroimage 2012; 63: 1038-1053.
65. Kolind S, Matthews L, Johansen-Berg H, et al. Myelin water imaging reflects clinical variability in multiple sclerosis. Neuroimage 2012; 60: 263-270.
66. Kitzler HH, Su J, Zeineh M, et al. Deficient MWF mapping in multiple sclerosis using 3D whole-brain multi-component relaxation MRI. Neuroimage 2012; 59: 2670-2677.
67. Wolff SD, Balaban RS,. Magnetization transfer contrast (MTC) and tissue water proton relaxation in vivo. Magn Reson Med 1989; 11: 135-144.
68. Stanisz GJ, Kecojevic A, Bronskill MJ, Henkelman RM,. Characterizing white matter with magnetization transfer and T2. Magn Reson Med 1999; 42: 1128-1136.
69. Levesque IR, Pike GB,. Characterizing healthy and diseased white matter using quantitative magnetization transfer and multicomponent T2 relaxometry: a unified view via a four-pool model. Magn Reson Med 2009; 62: 1487-1496.
70. Sled JG, Pike GB,. Quantitative imaging of magnetization transfer exchange and relaxation properties in vivo using MRI. Magn Reson Med 2001; 46: 923-931.
71. Graham SJ, Henkelman RM,. Pulsed magnetization transfer imaging: evaluation of technique. Radiology 1999; 212: 903-910.
72. Odrobina EE, Lam TYJ, Pun T, et al. MR properties of excised neural tissue following experimentally induced demyelination. NMR Biomed 2005; 18: 277-284.
73. Underhill HR, Rostomily RC, Mikheev AM, et al. Fast bound pool fraction imaging of the in vivo rat brain: association with myelin content and validation in the C6 glioma model. Neuroimage 2011; 54: 2052-2065.
74. Mottershead JP, Schmierer K, Clemence M, et al. High field MRI correlates of myelin content and axonal density in multiple sclerosis. J Neurol 2003; 250: 1293-1301.
75. Schmierer K, Tozer DJ, Scaravilli F, et al. Quantitative magnetization transfer imaging in postmortem multiple sclerosis brain. J Magn Reson Imaging 2007; 26: 41-51.
76. Blezer ELA, Bauer J, Brok HPM, et al. Quantitative MRI-pathology correlations of brain white matter lesions developing in a non-human primate model of multiple sclerosis. NMR Biomed 2007; 20: 90-103.
77. Bjarnson TA, Vavasour IM, Chia CLL, MacKay AL,. Characterization of the NMR behaviour of white matter in bovine brain. Magn Reson Med 2005; 54: 1072-1081.
78. Stanisz GJ, Webb S, Munro CA, et al. MR properties of excised neural tissue following experimentally induced inflammation. Magn Reson Med 2004; 51: 473-479.
79. Samsonov A, Alexander AL, Mossahebi P, et al. Quantitative MR imaging of two-pool magnetization transfer model parameters in myelin mutant shaking pup. Neuroimage 2012; 62: 1390-1398.
80. Ou X, Sun S-W, Liang H-F, et al. The MT pool size ratio and the DTI radial diffusivity may reflect the myelination in shiverer and control mice. NMR Biomed 2009; 22: 480-487.
81. Ou X, Sun S-W, Liang H-F, et al. Quantitative magnetization transfer measured pool-size ratio reflects optic nerve myelin content in ex vivo mice. Magn Reson Med 2009; 61: 364-371.
82. Dreha-Kulaczewski SF, Brockmann K, Henneke M, et al. Assessment of myelination in hypomyelinating disorders by quantitative MRI. J Magn Reson Imaging 2012; 36: 1329-1338.
83. Basser P, Pierpaoli C,. Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. J Magn Reson B 1996; 111: 209-219.
84. Song S-K, Sun S-W, Ramsbottom MJ, et al. Dysmyelination revealed through MRI as increased radial (but unchanged axial) diffusion of water. Neuroimage 2002; 17: 1429.
85. Harsan LA, Poulet P, Guignard B, et al. Brain dysmyelination and recovery assessment by noninvasive in vivo diffusion tensor magnetic resonance imaging. J Neurosci Res 2006; 83: 392-402.
86. Ruest T, Holmes WM, Barrie JA, et al. High-resolution diffusion tensor imaging of fixed brain in a mouse model of Pelizaeus-Merzbacher disease: comparison with quantitative measures of white matter pathology. NMR Biomed 2011; 24: 1369-1379.
87. Wu Y-C, Field AS, Duncan ID, et al. High b-value and diffusion tensor imaging in a canine model of dysmyelination and brain maturation. Neuroimage 2011; 58: 829-837.
88. Pierpaoli C, Basser PJ,. Toward a quantitative assessment of diffusion anisotropy. Magn Reson Med 1996; 36: 893-906.
89. Miller E, Widjaja E, Nilsson D, et al. Magnetic resonance imaging of a unique mutation in a family with Pelizaeus-Merzbacher disease. Am J Med Genet A 2010; 152A: 748-752.
90. Uchida N, Chen K, Dohse M, et al. Human neural stem cells induce functional myelination in mice with severe dysmyelination. Sci Transl Med 2012; 4: 155ra136.
91. Gupta N, Henry RG, Strober J, et al. Neural stem cell engraftment and myelination in the human brain. Sci Transl Med 2012; 4: 155ra137.
92. Goldman SA, Nedergaard M, Windrem MS,. Glial progenitor cell-based treatment and modeling of neurological disease. Science 2012; 338: 491-495.
93. Duncan I, Goldman S, Macklin W, et al. Stem cell therapy in multiple sclerosis: promise and controversy. Mult Scler 2008; 14: 541-546.
94. Wolf NI, Harting I, Boltshauser E, et al. Leukoencephalopathy with ataxia, hypodontia, and hypomyelination. Neurology 2005; 64: 1461-1464.
95. Bernard G, Thiffault I, Tetreault M, et al. Tremor-ataxia with central hypomyelination (TACH) leukodystrophy maps to chromosome 10q22.3-10q23.31. Neurogenetics 2010; 11: 457-464.
96. Cailloux F, Gauthier-Barichard F, Mimault C, et al. Genotype-phenotype correlation in inherited brain myelination defects due to proteolipid protein gene mutations. Clinical European Network on Brain Dysmyelinating Disease. Eur J Hum Genet 2000; 8: 837-845.
97. Wolf NI, Sistermans EA, Cundall M, et al. Three or more copies of the proteolipid protein gene PLP1 cause severe Pelizaeus-Merzbacher disease. Brain 2005; 128: 743-751.
98. Garbern JY, Yool DA, Moore GJ, et al. Patients lacking the major CNS myelin protein, proteolipid protein 1, develop length-dependent axonal degeneration in the absence of demyelination and inflammation. Brain 2002; 125: 551-561.
99. Rushton WA,. A theory of the effects of fibre size in medullated nerve. J Physiol 1951; 115: 101-122.
100. Frullano L, Zhu J, Miller RH, Wang Y,. Synthesis and characterization of a novel gadolinium-based contrast agent for magnetic resonance imaging of myelination. J Med Chem 2013; 56: 1629-1640.
101. Wu C, Wang C, Popescu DC, et al. A novel PET marker for in vivo quantification of myelination. Bioorg Med Chem 2010; 18: 8592-8599.
102. de Paula Faria D, de Vries EF, Sijbesma JW, et al. PET imaging of demyelination and remyelination in the cuprizone mouse model for multiple sclerosis: a comparison between [11C]CIC and [11C]MeDAS. Neuroimage 2014; 87: 395-402.
103. Wu C, Zhu J, Baeslack J, et al. Longitudinal positron emission tomography imaging for monitoring myelin repair in the spinal cord. Ann Neurol 2013; 74: 688-698.
104. Lee S, Chong S, Tuck S, et al. A rapid and reproducible assay for modeling myelination by oligodendrocytes using engineered nanofibers. Nat Protoc 2013; 8: 771-782.
105. Brüstle O, Jones KN, Learish RD, et al. Embryonic stem cell-derived glial precursors: a source of myelinating transplants. Science 1999; 285: 754-756.
106. Hu B-Y, Du Z-W, Zhang S-C,. Differentiation of human oligodendrocytes from pluripotent stem cells. Nat Protoc 2009; 4: 1614-1622.
107. Takahashi K, Yamanaka S,. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676.
108. Okita K, Yamanaka S,. Induced pluripotent stem cells: opportunities and challenges. Philos Trans R Soc Lond B Biol Sci 2011; 366: 2198-2207.
109. Wang S, Bates J, Li X, et al. Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination. Cell Stem Cell 2013; 12: 252-264.
110. Najm FJ, Lager AM, Zaremba A, et al. Transcription factor-mediated reprogramming of fibroblasts to expandable, myelinogenic oligodendrocyte progenitor cells. Nat Biotechnol 2013; 31: 426-433.
111. Yang N, Zuchero JB, Ahlenius H, et al. Generation of oligodendroglial cells by direct lineage conversion. Nat Biotechnol 2013; 31: 434-439.
112. Hockemeyer D, Wang H, Kiani S, et al. Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol 2011; 29: 731-734.
113. Mali P, Yang L, Esvelt KM, et al. RNA-guided human genome engineering via Cas9. Science 2013; 339: 823-826.
114. Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. Science 2013; 339: 819-823.